Cullinan Therapeutics Inc.
CGEM | NASDAQ
$21.53
+$0.18 (+0.84%)
Sep 22, 2026, 9:37 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | 18.94M | n/a |
Cost of Revenue | n/a | 306K | n/a | n/a | n/a | 62K |
Gross Profit | n/a | -306K | n/a | n/a | 18.94M | -62K |
Operating Income | -241.65M | -196.92M | -191.09M | 144.65M | -67.95M | -60.34M |
Interest Income | 22.21M | 29.66M | 21.63M | 6.61M | 477K | 888K |
Pretax Income | -219.88M | -167.46M | -169.22M | 151.32M | -67.49M | -59.46M |
Net Income | -219.88M | -167.38M | -153.16M | 111.21M | -65.57M | -51.8M |
Selling & General & Admin | 54.25M | 53.71M | 42.49M | 40.19M | 29.15M | 17.12M |
Research & Development | 187.4M | 142.9M | 148.16M | 91.95M | 57.75M | 43.21M |
Other Expenses | n/a | n/a | 440K | -276.79M | n/a | n/a |
Operating Expenses | 241.65M | 196.61M | 191.09M | -144.65M | 86.9M | 60.34M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | 894K | n/a | n/a | n/a | n/a |
Cost & Expenses | 241.65M | 196.92M | 191.09M | -144.65M | 86.9M | 60.34M |
Income Tax Expense | n/a | 117K | -14.12M | 42.12M | n/a | n/a |
Shares Outstanding (Basic) | 59.05M | 53.77M | 41.51M | 45.16M | 44.29M | 43.52M |
Shares Outstanding (Diluted) | 59.05M | 53.77M | 41.55M | 46.64M | 44.29M | 43.52M |
EPS (Basic) | -3.72 | -3.11 | -3.69 | 2.46 | -1.48 | -1.19 |
EPS (Diluted) | -3.72 | -3.11 | -3.69 | 2.38 | -1.48 | -1.19 |
EBITDA | -219.57M | -167.15M | -190.34M | -132.04M | -67.43M | -60.27M |
EBIT | -219.88M | -167.46M | -190.65M | -132.14M | -67.49M | -60.34M |
Depreciation & Amortization | 311K | 306K | 310K | 93K | 53K | 62K |
Add to Watchlist
Select watchlists to add or remove CGEM